Epidemiology of hematological malignancies, Ann Oncol, vol.18, issue.1, pp.3-8, 2007. ,
Incidence, survival and prevalence of myeloid malignancies in Europe, Eur J Cancer, vol.48, issue.17, pp.3257-3266, 2012. ,
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet, Blood, vol.115, issue.3, pp.453-474, 2010. ,
Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study, Br J Haematol, vol.162, issue.4, pp.509-516, 2013. ,
Long term instability and molecular mechanism of 5-azacytidine-induced DNA hypomethylation in normal and neoplastic tissues in vivo, Mol Pharmacol, vol.26, issue.3, pp.594-603, 1984. ,
Modes of action of the DNA Methyltransferase inhibitors azacytidine and decitabine, Int J Cancer, vol.123, issue.1, pp.8-13, 2008. ,
Pharmacokinetic and pharmacodynamic analysis of 5-aza-2?-deoxycytidine (decitabine) in the design of its doseschedule for cancer therapy, Clin Epigenetics, vol.5, issue.1, p.3, 2013. ,
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine, Proc Natl Acad Sci, vol.107, issue.16, pp.7473-7478, 2010. ,
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML, Blood, vol.123, issue.21, pp.3239-3246, 2014. ,
Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML, J Clin Oncol, vol.34, issue.15_suppl, pp.7000-7000, 2016. ,
SGI-110: DNA methyltransferase inhibitor oncolytic, Drugs Future, vol.38, issue.8, pp.535-543, 2013. ,
Efficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletion, Cancer Lett, vol.331, issue.1, pp.122-129, 2013. ,
A novel phase inversion-based process for the preparation of lipid nanocarriers, Pharm Res, vol.19, issue.6, pp.875-880, 2002. ,
Lipid nanocapsules: a new platform for nanomedicine, Int J Pharm, vol.379, issue.2, pp.201-209, 2009. ,
Nucleic-acid delivery using lipid nanocapsules, Curr Pharm Biotechnol, vol.17, issue.8, pp.723-727, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01392476
Toxicological study and efficacy of blank and paclitaxel-loaded lipid nanocapsules after i.v. administration in mice, Pharm Res, vol.27, issue.3, pp.421-430, 2010. ,
Absence of lung fibrosis after a single pulmonary delivery of lipid nanocapsules in rats, Int J Nanomedicine, vol.12, pp.8159-8170, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01813483
Lipid nanocapsules: a nanocarrier suitable for scale-up process, J Drug Delivery Sci Technol, vol.23, issue.6, pp.555-559, 2013. ,
Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia, Int J Nanomedicine, vol.12, pp.8427-8442, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01668530
randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia, JCO, vol.30, issue.21, pp.2670-2677, 2012. ,
High-performance liquid chromatographic analysis of chemical stability of 5-aza-2?-deoxycytidine, J Pharm Sci, vol.70, issue.11, pp.1228-1232, 1981. ,
Study of the time dependence of the stability of 5-aza-2?-deoxycytidine in acid medium, vol.25, pp.281-288 ,
Physicochemical stability of reconstituted decitabine (Dacogen®) solutions and ready-to-administer infusion bags when stored refrigerated or frozen, Pharmaceutical Technology in Hospital Pharmacy, vol.22017, p.145 ,
Lipid nanocapsules: readyto-use nanovectors for the aerosol delivery of paclitaxel, Eur J Pharm Biopharm, vol.73, issue.2, pp.239-246, 2009. ,
Gemcitabine versus modified gemcitabine: a review of several promising chemical modifications, Mol Pharm, vol.10, issue.2, pp.430-444, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-00787112
Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines, Biochem Pharmacol, vol.67, issue.3, pp.503-511, 2004. ,
Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models, Invest New Drugs, vol.29, issue.3, pp.456-466, 2011. ,
Mechanisms of resistance to 5-aza-2?-deoxycytidine in human cancer cell lines, Blood, vol.113, issue.3, pp.659-667, 2009. ,
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study, Lancet Oncol, vol.16, issue.9, pp.1099-1110, 2015. ,
Development and in vitro evaluation of a novel lipid nanocapsule formulation of etoposide ,
, Eur J Pharm Sci, vol.50, issue.2, pp.172-180, 2013.
Development and characterization of a novel lipid nanocapsule formulation of SN38 for oral administration, Eur J Pharm Biopharm, vol.79, issue.1, pp.181-188, 2011. ,
Lipid based nanocarrier system for the potential oral delivery of decitabine: formulation design, characterization, ex vivo, and in vivo assessment, Int J Pharm, vol.477, issue.1-2, pp.601-612, 2014. ,
Influence of lipid nanocapsules composition on their aptness to freeze-drying, Pharm Res, vol.22, issue.2, pp.285-292, 2005. ,
Intestinal absorption and activation of decitabine amino acid ester prodrugs mediated by peptide transporter PEPT1 and enterocyte enzymes, Int J Pharm, vol.541, issue.1-2, pp.64-71, 2018. ,
A carrier-mediated prodrug approach to improve the oral absorption of antileukemic drug decitabine, Mol Pharm, vol.10, issue.8, pp.3195-3202, 2013. ,
Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs, Antivir Chem Chemother, vol.23, issue.6, pp.223-230, 2014. ,
Successful emulation of IV decitabine pharmacokinetics with an oral Fixed-dose combination of the oral cytidine deaminase inhibitor (CDAi) E7727 with oral decitabine, in subjects with myelodysplastic syndromes (MDS): final data of phase 1 study, Am Soc Hematology, 2016. ,
Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine, Blood, vol.119, issue.5, pp.1240-1247, 2012. ,
In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles, Int J Pharm, vol.409, issue.1-2, pp.278-288, 2011. ,
Inhibition of ectopic glioma tumor growth by a potent ferrocenyl drug loaded into stealth lipid nanocapsules, Nanomedicine, vol.10, issue.8, pp.1667-1677, 2014. ,
The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability, Biomaterials, vol.31, issue.29, pp.7542-7554, 2010. ,
A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines, PLoS One, vol.5, issue.2, p.9001, 2010. ,
Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest, Mol Pharm, vol.10, issue.1, pp.337-352, 2013. ,
Hypomethylating agents reactivate FOXO3a in acute myeloid leukemia, Cell Cycle, vol.10, issue.14, pp.2323-2330, 2011. ,
Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2?-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method, Rapid Commun Mass Spectrom, vol.20, issue.7, pp.1117-1126, 2006. ,
Development and validation of a liquid chromatography-tandem mass spectrometry method for quantification of decitabine in rat plasma, Journal of Chromatography B, vol.899, pp.81-85, 2012. ,
Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy, Biomaterials, vol.96, pp.47-62, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01392469
Conventional versus stealth lipid nanoparticles: formulation and in vivo fate prediction through FRET monitoring, J Control Release, vol.188, pp.1-8, 2014. ,
In vivo evaluation of paclitaxel-loaded lipid nanocapsules after intravenous and oral administration on resistant tumor, Nanomedicine, vol.10, issue.4, pp.589-601, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01153494
, International Journal of Nanomedicine, vol.50, issue.24, 2020.